ArticlePlastic and reconstructive surgery. Global open2017
Liposomal Bupivacaine in Implant-Based Breast Reconstruction.
Article in Plastic and reconstructive surgery. Global open, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04360421 (Use of Liposomal Bupivacaine), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Use of Liposomal Bupivacaine (Exparel) In Expedited Recovery Following Lower Extremity Amputation
Who cites it
8 citing papers in PubMed, 18 citations in OpenAlex.
- Liposomal bupivacaine after reduction mammaplasty: is it worth the shot? A single-blind, breast-split randomized clinical trial.JPRAS open · 2026Article
- Liposomal Bupivacaine in Perioperative Analgesia: A Comprehensive Review of Clinical Efficacy, Safety, and Economic Context.Current pain and headache reports · 2026Review
- Does Liposomal Bupivacaine Reduce Postoperative Opioid Use in Tissue Expander Based Breast Reconstruction?Aesthetic plastic surgery · 2026Article
- Nanotechnology in Pain Management.Pharmaceutics · 2024Review
- Emerging Longer-Acting Local Anesthetic Formulations for Plastic Surgeons.Aesthetic surgery journal · 2024Article
- Optimizing perioperative outcomes in autologous breast reconstruction.Gland surgery · 2023Review
- Opioid-sparing Strategies in Alloplastic Breast Reconstruction: A Systematic Review.Plastic and reconstructive surgery. Global open · 2021Article
- Persistent Opioid Use and High-Risk Prescribing in Body Contouring Patients.Plastic and reconstructive surgery · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study evaluates the role of liposomal bupivacaine in implant-based breast reconstruction.
methodsA prospective, randomized, single-blind trial of liposomal bupivacaine in implant-based breast reconstruction was performed. Patients in the control arm were treated with 20 mL 0.25% bupivacaine with epinephrine 1:200,000 to each breast pocket. Patients in the experimental arm were treated with 10 mL 1.3% liposomal bupivacaine delivered to each breast pocket. Pain scores were recorded over the course of patients' hospital stay. Consumption of pain medications, benzodiazepines, and anti-emetics was monitored. Length of stay and other direct cost data were collected.
resultsTwenty-four patients were enrolled, with 12 women randomized to each arm. Average postoperative pain scores were 3.66 for patients in the control arm and 3.68 for patients in the experimental arm. Opioid consumption was 1.43 morphine equivalent dosing/h for patients in the control arm and 0.76 morphine equivalent dosing/h for patients in the experimental arm (
conclusionsLiposomal bupivacaine reduces opioid and benzodiazepine consumption, length of stay, and hospital charges. These data support a role for liposomal bupivacaine in implant-based breast reconstruction.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.